Ocular Therapeutix, OCUL is showing recent insider trading activity. Public SEC records indicate that Donald Notman recently Sold $31,843 worth of shares on 1 week ago. With that said, our editors here at politicsandwallstreet.com, are adding OCUL to our watchlist to see if this momentum continues.
Based on this transaction and a few others from Corporate Insiders of OCUL that Bought 16,180,270 worth of shares in the last 3 months, the Insider Confidence level of Ocular Therapeutix is trending Up.
Since these insiders have unique insights into what's happening at Ocular Therapeutix, this might serve as an indicator of where it is headed.
Here is a list of the latest insider activity for OCUL:
In addition, TradingView issued a buy rating for OCUL over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bullish short-term outlook.
Here is a bit more on Ocular Therapeutix, OCUL but please do your own research.
OCUL Summary: Ocular Therapeutix, Inc. is a biopharmaceutical company. It is focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. The Company develops and markets eye care products. Ocular Therapeutix, Inc. is headquartered in Bedford, Massachusetts.
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. Click here for more on Tipranks.com.
This information was sourced from various 3rd party public sources but to get the best insight into insider activity related to OCUL, you should consider joining TipRanks.com.
PoliticsAndWallStreet.com
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================
Based on this transaction and a few others from Corporate Insiders of OCUL that Bought 16,180,270 worth of shares in the last 3 months, the Insider Confidence level of Ocular Therapeutix is trending Up.
Since these insiders have unique insights into what's happening at Ocular Therapeutix, this might serve as an indicator of where it is headed.
Here is a list of the latest insider activity for OCUL:
- Donald Notman - officer: Chief Medical Officer, Sold $31,843 worth of shares on 1 week ago
- Rabia Ozden - officer: Chief Financial Officer, Sold $38,432 worth of shares on 1 week ago
- Philip Strassburger - officer: General Counsel, Sold $33,813 worth of shares on 1 week ago
- Christopher White - officer: Chief Business Officer, Sold $25,478 worth of shares on 1 week ago
In addition, TradingView issued a buy rating for OCUL over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bullish short-term outlook.
Here is a bit more on Ocular Therapeutix, OCUL but please do your own research.
OCUL Summary: Ocular Therapeutix, Inc. is a biopharmaceutical company. It is focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. The Company develops and markets eye care products. Ocular Therapeutix, Inc. is headquartered in Bedford, Massachusetts.
- Recent Last Price: $5.00
- Price Change: -$0.04, -0.79%
- Yearly Gain: 17.48%
- Market Cap: $545.58M
- P/E Ratio: -4.533
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. Click here for more on Tipranks.com.
This information was sourced from various 3rd party public sources but to get the best insight into insider activity related to OCUL, you should consider joining TipRanks.com.
PoliticsAndWallStreet.com
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================
